stockrow
Saturday 7 November 2026
Export EXOZ’s income statement to Excel — free account
eXoZymes Inc.
EXOZ Healthcare Biotechnology
eXoZymes Inc.’s revenue for fiscal 2023 (year ended December 2023) was $70,100.00.
- EPS
- −17.9%
- Free cash flow
- −3.25%
- Total debt
- −52.9%
Quarter to June 2026, against a year earlier
4.40
0.29
+7.06%
Follow EXOZ
Alert me
eXoZymes Inc. (EXOZ) P/E ratio
eXoZymes Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELTX Elicio Therapeutics, Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| EXOZ eXoZymes Inc. | n/m |
| GRCE Grace Therapeutics, Inc. compare | n/m |
| HYPD Hyperion DeFi, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| IBO Impact Biomedical Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)